Current good manufacturing practices for blood and blood components: notification of consignees receiving blood and blood components at increased risk for transmitting HIV infection--FDA. Final rule.
The Food and Drug Administration (FDA) is amending the biologics regulations to require that blood establishments (including plasma establishments) prepare and follow written procedures for appropriate action when it is determined that Whole Blood, blood components (including recovered plasma), Source Plasma and Source Leukocytes at increased risk for transmitting human immunodeficiency virus (HIV) infection have been collected. This final rule requires that when a donor who previously donated blood is tested on a later donation in accordance with the regulations and tests repeatedly reactive for antibody to HIV, the blood establishment shall perform more specific testing using a licensed test, if available, and notify consignees who received Whole Blood, blood components, Source Plasma or Source Leukocytes from prior collections so that appropriate action is taken. Blood establishments and consignees are required to quarantine previously collected Whole Blood, blood components, Source Plasma and Source Leukocytes from such donors, and if appropriate, notify transfusion recipients. The Health Care Financing Administration (HCFA) is also issuing a final rule, published elsewhere in this Federal Register, which requires all transfusion services subject to HCFA's conditions of Medicare participation for hospitals to notify transfusion recipients who have received Whole Blood or blood components from a donor whose subsequent donation test results are positive for antibody to HIV (hereinafter referred to as HCFA's final rule). FDA is requiring transfusion services that do not participate in Medicare and are, therefore, not subject to HCFA's final rule, to take steps to notify transfusion recipients. FDA is taking this action to help ensure the continued safety of the blood supply, and to help ensure that information is provided to consignees of Whole Blood, blood components, Source Plasma and Source Leukocytes and to recipients of Whole Blood and blood components from a donor whose subsequent donation tests positive for antibody to HIV.
D001771:Blood Banks / Q000331:legislation & jurisprudence / Q000592:standards*; D016913:Blood Component Transfusion / Q000009:adverse effects / Q000592:standards*; D001782:Blood Donors; D001803:Blood Transfusion / Q000592:standards*; D014487:Centers for Medicare and Medicaid Services, U.S.; D016358:Contact Tracing; D015658:HIV Infections / Q000453:epidemiology / Q000209:etiology / Q000635:transmission*; D006801:Humans; D010344:Patient Advocacy / Q000331:legislation & jurisprudence / Q000592:standards*; D012307:Risk Factors; D065227:Transfusion Reaction; D014481:United States / Q000453:epidemiology; D014483:United States Dept. of Health and Human Services; D014486:United States Food and Drug Administration